- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joshua Benner Discusses the Importance of PQA's New Opioid Measures
The new opioid quality measures by the Pharmacy Quality Alliance are a first step forward for improving use of prescription opioids.
At its 10th Annual Meeting in Arlington, Virginia, the Pharmacy Quality Alliance announced its new opioid quality measures, and RxAnte helped in the development and testing of these measures, explained Joshua Benner, PharmD, ScD, executive vice president of strategy and corporate development at Millennium Health and former president and chief executive officer of RxAnte.
The measures are just a first step, but what is important is that they develop a common definition of what appropriate use of prescription opioids actually is, Dr Benner said.
"As we develop experience using those measures in practice, we'll learn more about how they should be refined over time," he said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
